Cabaletta Bio

Steven Nichtberger, M.D., President and CEO 

Oct. 11 | 10:45am | Oxford Biomedica Ballroom 

Philadelphia, PA 

(NASDAQ: CABA) 

In-person Presentation 

Cabaletta Bio is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies that have the potential to provide a deep and durable, perhaps curative, treatment for patients with autoimmune diseases. The CABA™ platform, in combination with Cabaletta Bio’s proprietary technology, has advanced a growing pipeline that currently includes potential treatments for patients with mucosal pemphigus vulgaris, MuSK-associated myasthenia gravis, PLA2R-associated membranous nephropathy, mucocutaneous pemphigus vulgaris, and hemophilia A with FVIII alloantibodies. 

www.cabalettabio.com 

 



By using this website you agree to accept our Privacy Policy and Terms & Conditions